Q2 2016 13F Holders as of 30 Jun 2016
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
13.1M
-
Number of holders
-
113
-
Total 13F shares, excl. options
-
17.2M
-
Shares change
-
+804K
-
Total reported value, excl. options
-
$667M
-
Value change
-
+$29.3M
-
Put/Call ratio
-
0.54
-
Number of buys
-
63
-
Number of sells
-
-53
-
Price
-
$38.79
Significant Holders of EAGLE PHARMACEUTICALS, INC. - Common Stock (EGRX) as of Q2 2016
160 filings reported holding EGRX - EAGLE PHARMACEUTICALS, INC. - Common Stock as of Q2 2016.
EAGLE PHARMACEUTICALS, INC. - Common Stock (EGRX) has 113 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 17.2M shares
.
Largest 10 shareholders include ProQuest Associates IV LLC (4.78M shares), JANUS CAPITAL MANAGEMENT LLC (1.49M shares), ORBIMED ADVISORS LLC (1.04M shares), Hudson Executive Capital LP (951K shares), MORGAN STANLEY (715K shares), Park West Asset Management LLC (630K shares), GREAT POINT PARTNERS LLC (548K shares), JW Asset Management, LLC (525K shares), Cormorant Asset Management, LLC (506K shares), and Consonance Capital Management LP (482K shares).
This table shows the top 113 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.